NasdaqGS:EXELBiotechs
Does Exelixis’ 2026 Revenue Guidance and Zanzalintinib Push Change The Bull Case For EXEL?
Exelixis recently released preliminary 2025 results, projecting total revenues of about US$2.32 billion and net product revenues of about US$2.12 billion, while guiding 2026 total revenues to US$2.53–2.63 billion and net product revenues to US$2.33–2.43 billion, alongside updates on its oncology pipeline and business.
At the same time, Exelixis moved to expand beyond cabozantinib by advancing zanzalintinib toward a potential first commercial indication and launching a new colorectal cancer...